COVID-19 or treatment associated immunosuppression may trigger hepatitis B virus reactivation: A case report

Yi-Feng Wu,Wan-Jun Yu,Yu-Hua Jiang,Yin Chen,Bo Zhang,Rui-Bing Zhen,Jun-Tao Zhang,Yi-Ping Wang,Qiang Li,Feng Xu,Yan-Jun Shi,Xian-Peng Li
DOI: https://doi.org/10.12998/wjcc.v9.i19.5266
2021-07-06
World Journal of Clinical Cases
Abstract:BACKGROUND: Since the initial recognition of coronavirus disease 2019 (COVID-19) in Wuhan, this infectious disease has spread to most areas of the world. The pathogenesis of COVID-19 is yet unclear. Hepatitis B virus (HBV) reactivation occurring in COVID-19 patients has not yet been reported.CASE SUMMARY: A 45-year-old hepatitis B man with long-term use of adefovir dipivoxil and entecavir for antiviral therapy had HBV reactivation after being treated with methylprednisolone for COVID-19 for 6 d.CONCLUSION: COVID-19 or treatment associated immunosuppression may trigger HBV reactivation.
medicine, general & internal
What problem does this paper attempt to address?